{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T05:10:51Z","timestamp":1793250651463,"version":"4.5.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,2,18]],"date-time":"2020-02-18T00:00:00Z","timestamp":1581984000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,2,18]],"date-time":"2020-02-18T00:00:00Z","timestamp":1581984000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Empagliflozin (empa), a selective sodium\u2013glucose cotransporter (SGLT)2 inhibitor, reduced cardiovascular mortality and hospitalization for heart failure in patients with type 2 diabetes at high cardiovascular risk independent of glycemic control. The cardiovascular protective effect of empa was evaluated in an experimental model of metabolic syndrome, the obese ZSF1 rat, and its\u2019 lean control.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Lean and obese ZSF1 rats were either non-treated or treated with empa (30\u00a0mg\/kg\/day) for 6\u00a0weeks. Vascular reactivity was assessed using mesenteric artery rings, systolic blood pressure by tail-cuff sphygmomanometry, heart function and structural changes by echocardiography, and protein expression levels by Western blot analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Empa treatment reduced blood glucose levels from 275 to 196\u00a0mg\/dl in obese ZSF1 rats whereas normoglycemia (134\u00a0mg\/dl) was present in control lean ZSF1 rats and was unaffected by empa. Obese ZSF1 rats showed increased systolic blood pressure, and blunted endothelium-dependent relaxations associated with the appearance of endothelium-dependent contractile responses (EDCFs) compared to control lean rats. These effects were prevented by the empa treatment. Obese ZSF1 rats showed increased weight of the heart and of the left ventricle volume without the presence of diastolic or systolic dysfunction, which were improved by the empa treatment. An increased expression level of senescence markers (p53, p21, p16), tissue factor, VCAM-1, SGLT1 and SGLT2 and a down-regulation of eNOS were observed in the aortic inner curvature compared to the outer one in the control lean rats, which were prevented by the empa treatment. In the obese ZSF1 rats, no such effects were observed. The empa treatment reduced the increased body weight and weight of lungs, spleen, liver and perirenal fat, hyperglycemia and the increased levels of total cholesterol and triglycerides in obese ZSF1 rats, and increased blood ketone levels and urinary glucose excretion in control lean and obese ZSF1 rats.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Empa reduced glucose levels by 28% and improved both endothelial function and cardiac remodeling in the obese ZSF1 rat. Empa also reduced the increased expression level of senescence, and atherothrombotic markers at arterial sites at risk in the control lean, but not obese, ZSF1 rat.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12933-020-00997-7","type":"journal-article","created":{"date-parts":[[2020,2,18]],"date-time":"2020-02-18T09:02:54Z","timestamp":1582016574000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":120,"title":["Empagliflozin improved systolic blood pressure, endothelial dysfunction and heart remodeling in the metabolic syndrome ZSF1 rat"],"prefix":"10.1186","volume":"19","author":[{"given":"Sin-Hee","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Akmal","family":"Farooq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Gaertner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Bruckert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul Wahid","family":"Qureshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun-Ho","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Djamel","family":"Benrahla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Pollet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Stephan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Ohlmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marc","family":"Lessinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Mayoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyril","family":"Auger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Morel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie B.","family":"Schini-Kerth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,18]]},"reference":[{"issue":"4","key":"997_CR1","doi-asserted-by":"publisher","first-page":"683","DOI":"10.2337\/diacare.24.4.683","volume":"24","author":"B Isomaa","year":"2001","unstructured":"Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, Taskinen MR, Groop L. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001;24(4):683\u20139.","journal-title":"Diabetes Care"},{"issue":"11","key":"997_CR2","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1093\/aje\/kwf145","volume":"156","author":"DE Laaksonen","year":"2002","unstructured":"Laaksonen DE, Lakka HM, Niskanen LK, Kaplan GA, Salonen JT, Lakka TA. Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. Am J Epidemiol. 2002;156(11):1070\u20137.","journal-title":"Am J Epidemiol"},{"issue":"21","key":"997_CR3","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1001\/jama.288.21.2709","volume":"288","author":"HM Lakka","year":"2002","unstructured":"Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002;288(21):2709\u201316.","journal-title":"JAMA"},{"issue":"11","key":"997_CR4","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.2337\/diacare.26.11.3153","volume":"26","author":"C Lorenzo","year":"2003","unstructured":"Lorenzo C, Okoloise M, Williams K, Stern MP, Haffner SM. The metabolic syndrome as predictor of type 2 diabetes: the San Antonio heart study. Diabetes Care. 2003;26(11):3153\u20139.","journal-title":"Diabetes Care"},{"issue":"1","key":"997_CR5","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1139\/h06-095","volume":"32","author":"S Desroches","year":"2007","unstructured":"Desroches S, Lamarche B. The evolving definitions and increasing prevalence of the metabolic syndrome. Appl Physiol Nutr Metab Physiologie appliquee, nutrition et metabolisme. 2007;32(1):23\u201332.","journal-title":"Appl Physiol Nutr Metab Physiologie appliquee, nutrition et metabolisme"},{"issue":"6","key":"997_CR6","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1097\/MAJ.0b013e318065c3a1","volume":"333","author":"GD Kolovou","year":"2007","unstructured":"Kolovou GD, Anagnostopoulou KK, Salpea KD, Mikhailidis DP. The prevalence of metabolic syndrome in various populations. Am J Med Sci. 2007;333(6):362\u201371.","journal-title":"Am J Med Sci"},{"key":"997_CR7","doi-asserted-by":"publisher","first-page":"77","DOI":"10.2337\/diaclin.26.2.77","volume":"26","author":"MJ Fowler","year":"2008","unstructured":"Fowler MJ. Microvascular and macrovascular complications of diabetes. Clin Diabetes. 2008;26:77\u201382.","journal-title":"Clin Diabetes"},{"issue":"6","key":"997_CR8","doi-asserted-by":"publisher","first-page":"2510","DOI":"10.1161\/01.CIR.88.6.2510","volume":"88","author":"MT Johnstone","year":"1993","unstructured":"Johnstone MT, Creager SJ, Scales KM, Cusco JA, Lee BK, Creager MA. Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. Circulation. 1993;88(6):2510\u20136.","journal-title":"Circulation"},{"issue":"8","key":"997_CR9","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/BF00429099","volume":"35","author":"GE McVeigh","year":"1992","unstructured":"McVeigh GE, Brennan GM, Johnston GD, McDermott BJ, McGrath LT, Henry WR, Andrews JW, Hayes JR. Impaired endothelium-dependent and independent vasodilation in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia. 1992;35(8):771\u20136.","journal-title":"Diabetologia"},{"issue":"3","key":"997_CR10","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/0735-1097(95)00522-6","volume":"27","author":"SB Williams","year":"1996","unstructured":"Williams SB, Cusco JA, Roddy MA, Johnstone MT, Creager MA. Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. J Am Coll Cardiol. 1996;27(3):567\u201374.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"997_CR11","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/0735-1097(96)82380-1","volume":"28","author":"P Clarkson","year":"1996","unstructured":"Clarkson P, Celermajer DS, Donald AE, Sampson M, Sorensen KE, Adams M, Yue DK, Betteridge DJ, Deanfield JE. Impaired vascular reactivity in insulin-dependent diabetes mellitus is related to disease duration and low density lipoprotein cholesterol levels. J Am Coll Cardiol. 1996;28(3):573\u20139.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"997_CR12","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1172\/JCI114521","volume":"85","author":"B Tesfamariam","year":"1990","unstructured":"Tesfamariam B, Brown ML, Deykin D, Cohen RA. Elevated glucose promotes generation of endothelium-derived vasoconstrictor prostanoids in rabbit aorta. J Clin Investig. 1990;85(3):929\u201332.","journal-title":"J Clin Investig"},{"issue":"3 Pt 2","key":"997_CR13","first-page":"H845","volume":"269","author":"GM Pieper","year":"1995","unstructured":"Pieper GM, Meier DA, Hager SR. Endothelial dysfunction in a model of hyperglycemia and hyperinsulinemia. Am J Physiol. 1995;269(3 Pt 2):H845\u201350.","journal-title":"Am J Physiol"},{"issue":"1 Pt 2","key":"997_CR14","first-page":"H219","volume":"265","author":"HG Bohlen","year":"1993","unstructured":"Bohlen HG, Lash JM. Topical hyperglycemia rapidly suppresses EDRF-mediated vasodilation of normal rat arterioles. Am J Physiol. 1993;265(1 Pt 2):H219\u201325.","journal-title":"Am J Physiol"},{"issue":"2","key":"997_CR15","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1096\/fj.00-0051com","volume":"15","author":"E Vasile","year":"2001","unstructured":"Vasile E, Tomita Y, Brown LF, Kocher O, Dvorak HF. Differential expression of thymosin beta-10 by early passage and senescent vascular endothelium is modulated by VPF\/VEGF: evidence for senescent endothelial cells in vivo at sites of atherosclerosis. FASEB J. 2001;15(2):458\u201366.","journal-title":"FASEB J"},{"issue":"13","key":"997_CR16","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1161\/01.CIR.0000013836.85741.17","volume":"105","author":"T Minamino","year":"2002","unstructured":"Minamino T, Miyauchi H, Yoshida T, Ishida Y, Yoshida H, Komuro I. Endothelial cell senescence in human atherosclerosis: role of telomere in endothelial dysfunction. Circulation. 2002;105(13):1541\u20134.","journal-title":"Circulation"},{"issue":"1","key":"997_CR17","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1161\/ATVBAHA.110.215061","volume":"31","author":"A Kumar","year":"2011","unstructured":"Kumar A, Kim CS, Hoffman TA, Naqvi A, Dericco J, Jung SB, Lin Z, Jain MK, Irani K. p53 impairs endothelial function by transcriptionally repressing Kruppel-Like Factor 2. Arterioscler Thromb Vasc Biol. 2011;31(1):133\u201341.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"22","key":"997_CR18","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117\u201328.","journal-title":"N Engl J Med"},{"issue":"7","key":"997_CR19","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644\u201357.","journal-title":"N Engl J Med"},{"issue":"4","key":"997_CR20","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347\u201357.","journal-title":"N Engl J Med"},{"issue":"17","key":"997_CR21","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1161\/CIRCULATIONAHA.118.035759","volume":"138","author":"SE Inzucchi","year":"2018","unstructured":"Inzucchi SE, Kosiborod M, Fitchett D, Wanner C, Hehnke U, Kaspers S, George JT, Zinman B. Improvement in cardiovascular outcomes with empagliflozin is independent of glycemic control. Circulation. 2018;138(17):1904\u20137.","journal-title":"Circulation"},{"issue":"11","key":"997_CR22","doi-asserted-by":"publisher","first-page":"e112394","DOI":"10.1371\/journal.pone.0112394","volume":"9","author":"M Oelze","year":"2014","unstructured":"Oelze M, Kroller-Schon S, Welschof P, Jansen T, Hausding M, Mikhed Y, Stamm P, Mader M, Zinssius E, Agdauletova S, et al. The sodium\u2013glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity. PLoS ONE. 2014;9(11):e112394.","journal-title":"PLoS ONE"},{"issue":"1","key":"997_CR23","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12933-019-0849-6","volume":"18","author":"H-C Lee","year":"2019","unstructured":"Lee H-C, Shiou Y-L, Jhuo S-J, Chang C-Y, Liu P-L, Jhuang W-J, Dai Z-K, Chen W-Y, Chen Y-F, Lee A-S. The sodium\u2013glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats. Cardiovasc Diabetol. 2019;18(1):45.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"997_CR24","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s12933-016-0473-7","volume":"15","author":"H Kusaka","year":"2016","unstructured":"Kusaka H, Koibuchi N, Hasegawa Y, Ogawa H, Kim-Mitsuyama S. Empagliflozin lessened cardiac injury and reduced visceral adipocyte hypertrophy in prediabetic rats with metabolic syndrome. Cardiovasc Diabetol. 2016;15(1):157.","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"997_CR25","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1177\/1074248418763808","volume":"23","author":"F Younis","year":"2018","unstructured":"Younis F, Leor J, Abassi Z, Landa N, Rath L, Hollander K, Naftali-Shani N, Rosenthal T. Beneficial effect of the SGLT2 inhibitor empagliflozin on glucose homeostasis and cardiovascular parameters in the cohen rosenthal diabetic hypertensive (CRDH) rat. J Cardiovasc Pharmacol Ther. 2018;23(4):358\u201371.","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"1","key":"997_CR26","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12933-019-0816-2","volume":"18","author":"C Li","year":"2019","unstructured":"Li C, Zhang J, Xue M, Li X, Han F, Liu X, Xu L, Lu Y, Cheng Y, Li T, et al. SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart. Cardiovasc Diabetol. 2019;18(1):15.","journal-title":"Cardiovasc Diabetol"},{"key":"997_CR27","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.redox.2017.06.009","volume":"13","author":"S Steven","year":"2017","unstructured":"Steven S, Oelze M, Hanf A, Kroller-Schon S, Kashani F, Roohani S, Welschof P, Kopp M, Godtel-Armbrust U, Xia N, et al. The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats. Redox Biol. 2017;13:370\u201385.","journal-title":"Redox Biol"},{"key":"997_CR28","doi-asserted-by":"publisher","first-page":"113677","DOI":"10.1016\/j.bcp.2019.113677","volume":"170","author":"A Aragon-Herrera","year":"2019","unstructured":"Aragon-Herrera A, Feijoo-Bandin S, Otero Santiago M, Barral L, Campos-Toimil M, Gil-Longo J, Costa Pereira TM, Garcia-Caballero T, Rodriguez-Segade S, Rodriguez J, et al. Empagliflozin reduces the levels of CD36 and cardiotoxic lipids while improving autophagy in the hearts of Zucker diabetic fatty rats. Biochem Pharmacol. 2019;170:113677.","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"997_CR29","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12933-018-0750-8","volume":"17","author":"AR Aroor","year":"2018","unstructured":"Aroor AR, Das NA, Carpenter AJ, Habibi J, Jia G, Ramirez-Perez FI, Martinez-Lemus L, Manrique-Acevedo CM, Hayden MR, Duta C, et al. Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury. Cardiovasc Diabetol. 2018;17(1):108.","journal-title":"Cardiovasc Diabetol"},{"key":"997_CR30","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.14233","author":"S Khemais-Benkhiat","year":"2019","unstructured":"Khemais-Benkhiat S, Belcastro E, Idris-Khodja N, Park SH, Amoura L, Abbas M, Auger C, Kessler L, Mayoux E, Toti F, et al. Angiotensin II-induced redox-sensitive SGLT1 and 2 expression promotes high glucose-induced endothelial cell senescence. J Cell Mol Med. 2019. https:\/\/doi.org\/10.1111\/jcmm.14233.","journal-title":"J Cell Mol Med"},{"issue":"2","key":"997_CR31","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1124\/jpet.108.145326","volume":"328","author":"S Dal-Ros","year":"2009","unstructured":"Dal-Ros S, Bronner C, Schott C, Kane MO, Chataigneau M, Schini-Kerth VB, Chataigneau T. Angiotensin II-induced hypertension is associated with a selective inhibition of endothelium-derived hyperpolarizing factor-mediated responses in the rat mesenteric artery. J Pharmacol Exp Ther. 2009;328(2):478\u201386.","journal-title":"J Pharmacol Exp Ther"},{"issue":"10","key":"997_CR32","first-page":"1018","volume":"112","author":"S Glagov","year":"1988","unstructured":"Glagov S, Zarins C, Giddens DP, Ku DN. Hemodynamics and atherosclerosis Insights and perspectives gained from studies of human arteries. Arch Pathol Lab Med. 1988;112(10):1018\u201331.","journal-title":"Arch Pathol Lab Med"},{"key":"997_CR33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911303","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Belohlavek J, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019. https:\/\/doi.org\/10.1056\/NEJMoa1911303.","journal-title":"N Engl J Med"},{"issue":"2","key":"997_CR34","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1177\/1479164114559852","volume":"12","author":"SE Inzucchi","year":"2015","unstructured":"Inzucchi SE, Zinman B, Wanner C, Ferrari R, Fitchett D, Hantel S, Espadero RM, Woerle HJ, Broedl UC, Johansen OE. SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials. Diabetes Vasc Dis Res. 2015;12(2):90\u2013100.","journal-title":"Diabetes Vasc Dis Res"},{"issue":"6","key":"997_CR35","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1161\/CIRCHEARTFAILURE.113.000539","volume":"6","author":"N Hamdani","year":"2013","unstructured":"Hamdani N, Franssen C, Louren\u00e7o A, Falc\u00e3o-Pires I, Fontoura D, Leite S, Plettig L, L\u00f3pez B, Ottenheijm CA, Becher PM, et al. Myocardial titin hypophosphorylation importantly contributes to heart failure with preserved ejection fraction in a rat metabolic risk model. Circ Heart Fail. 2013;6(6):1239\u201349.","journal-title":"Circ Heart Fail"},{"issue":"12","key":"997_CR36","doi-asserted-by":"publisher","first-page":"H1556","DOI":"10.1152\/ajpheart.00076.2015","volume":"308","author":"S Leite","year":"2015","unstructured":"Leite S, Oliveira-Pinto J, Tavares-Silva M, Abdellatif M, Fontoura D, Falc\u00e3o-Pires I, Leite-Moreira AF, Louren\u00e7o AP. Echocardiography and invasive hemodynamics during stress testing for diagnosis of heart failure with preserved ejection fraction: an experimental study. Am J Physiol Heart Circ Physiol. 2015;308(12):H1556\u201363.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"4","key":"997_CR37","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1081\/JDI-100100882","volume":"22","author":"SP Tofovic","year":"2000","unstructured":"Tofovic SP, Kusaka H, Kost CK Jr, Bastacky S. Renal function and structure in diabetic, hypertensive, obese ZDFxSHHF-hybrid rats. Ren Fail. 2000;22(4):387\u2013406.","journal-title":"Ren Fail"},{"key":"997_CR38","doi-asserted-by":"publisher","first-page":"265","DOI":"10.2147\/DMSO.S58786","volume":"7","author":"SP Vickers","year":"2014","unstructured":"Vickers SP, Cheetham SC, Headland KR, Dickinson K, Grempler R, Mayoux E, Mark M, Klein T. Combination of the sodium\u2013glucose cotransporter-2 inhibitor empagliflozin with orlistat or sibutramine further improves the body-weight reduction and glucose homeostasis of obese rats fed a cafeteria diet. Diabetes Metab Syndr Obes Targets Ther. 2014;7:265\u201375.","journal-title":"Diabetes Metab Syndr Obes Targets Ther"},{"issue":"1","key":"997_CR39","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s12933-019-0820-6","volume":"18","author":"DD Adingupu","year":"2019","unstructured":"Adingupu DD, G\u00f6pel SO, Gr\u00f6nros J, Behrendt M, Sotak M, Miliotis T, Dahlqvist U, Gan L-M, J\u00f6nsson-Rylander A-C. SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob\/ob\u2009\u2212\/\u2212\u2009mice. Cardiovasc Diabetol. 2019;18(1):16.","journal-title":"Cardiovasc Diabetol"},{"issue":"5","key":"997_CR40","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.jacbts.2018.07.006","volume":"3","author":"S Verma","year":"2018","unstructured":"Verma S, Rawat S, Ho KL, Wagg CS, Zhang L, Teoh H, Dyck JE, Uddin GM, Oudit GY, Mayoux E, et al. Empagliflozin increases cardiac energy production in diabetes: novel translational insights into the heart failure benefits of SGLT2 inhibitors. JACC Basic Transl Sci. 2018;3(5):575\u201387.","journal-title":"JACC Basic Transl Sci"},{"issue":"1","key":"997_CR41","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12933-016-0489-z","volume":"16","author":"J Habibi","year":"2017","unstructured":"Habibi J, Aroor AR, Sowers JR, Jia G, Hayden MR, Garro M, Barron B, Mayoux E, Rector RS, Whaley-Connell A, et al. Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes. Cardiovasc Diabetol. 2017;16(1):9.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"997_CR42","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jacbts.2018.11.010","volume":"4","author":"KA Connelly","year":"2019","unstructured":"Connelly KA, Zhang Y, Visram A, Advani A, Batchu SN, Desjardins J-F, Thai K, Gilbert RE. Empagliflozin improves diastolic function in a nondiabetic rodent model\u00a0of heart failure with preserved\u00a0ejection\u00a0fraction. JACC Basic Transl Sci. 2019;4(1):27\u201337.","journal-title":"JACC Basic Transl Sci"},{"issue":"3","key":"997_CR43","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.jash.2016.01.009","volume":"10","author":"G Kimura","year":"2016","unstructured":"Kimura G. Importance of inhibiting sodium\u2013glucose cotransporter and its compelling indication in type 2 diabetes: pathophysiological hypothesis. J Am Soc Hypertens JASH. 2016;10(3):271\u20138.","journal-title":"J Am Soc Hypertens JASH"},{"issue":"1","key":"997_CR44","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jdiacomp.2015.10.012","volume":"30","author":"J McMurray","year":"2016","unstructured":"McMurray J. EMPA-REG\u2014he \u201cdiuretic hypothesis\u201d. J Diabetes Complicat. 2016;30(1):3\u20134.","journal-title":"J Diabetes Complicat"},{"issue":"2","key":"997_CR45","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.numecd.2009.08.006","volume":"20","author":"K Tziomalos","year":"2010","unstructured":"Tziomalos K, Athyros VG, Karagiannis A, Mikhailidis DP. Endothelial dysfunction in metabolic syndrome: prevalence, pathogenesis and management. Nutr Metab Cardiovasc Dis NMCD. 2010;20(2):140\u20136.","journal-title":"Nutr Metab Cardiovasc Dis NMCD"},{"issue":"9","key":"997_CR46","doi-asserted-by":"publisher","first-page":"L1027","DOI":"10.1152\/ajplung.00167.2015","volume":"309","author":"Y Han","year":"2015","unstructured":"Han Y, Cho YE, Ayon R, Guo R, Youssef KD, Pan M, Dai A, Yuan JX, Makino A. SGLT inhibitors attenuate NO-dependent vascular relaxation in the pulmonary artery but not in the coronary artery. Am J Physiol Lung Cell Mol Physiol. 2015;309(9):L1027\u201336.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"997_CR47","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3389\/fcvm.2016.00043","volume":"3","author":"HM Salim","year":"2016","unstructured":"Salim HM, Fukuda D, Yagi S, Soeki T, Shimabukuro M, Sata M. Glycemic control with ipragliflozin, a novel selective SGLT2 inhibitor, ameliorated endothelial dysfunction in streptozotocin-induced diabetic mouse. Front Cardiovasc Med. 2016;3:43.","journal-title":"Front Cardiovasc Med"},{"issue":"12","key":"997_CR48","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1161\/01.RES.0000022161.42655.98","volume":"90","author":"J Chen","year":"2002","unstructured":"Chen J, Brodsky SV, Goligorsky DM, Hampel DJ, Li H, Gross SS, Goligorsky MS. Glycated collagen I induces premature senescence-like phenotypic changes in endothelial cells. Circ Res. 2002;90(12):1290\u20138.","journal-title":"Circ Res"},{"issue":"1","key":"997_CR49","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.ddstr.2007.10.006","volume":"4","author":"J Chen","year":"2007","unstructured":"Chen J, Park HC, Patschan S, Brodsky SV, Gealikman O, Kuo MC, Li H, Addabbo F, Zhang F, Nasjletti A, et al. Premature vascular senescence in metabolic syndrome: could it be prevented and reversed by a selenorganic antioxidant and peroxynitrite scavenger ebselen? Drug Discov Today Ther Strateg. 2007;4(1):93\u20139.","journal-title":"Drug Discov Today Ther Strateg"},{"issue":"45","key":"997_CR50","doi-asserted-by":"publisher","first-page":"17018","DOI":"10.1073\/pnas.0607873103","volume":"103","author":"T Hayashi","year":"2006","unstructured":"Hayashi T, Matsui-Hirai H, Miyazaki-Akita A, Fukatsu A, Funami J, Ding QF, Kamalanathan S, Hattori Y, Ignarro LJ, Iguchi A. Endothelial cellular senescence is inhibited by nitric oxide: implications in atherosclerosis associated with menopause and diabetes. Proc Natl Acad Sci USA. 2006;103(45):17018\u201323.","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-020-00997-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12933-020-00997-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-020-00997-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,15]],"date-time":"2022-10-15T21:11:08Z","timestamp":1665868268000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-020-00997-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,18]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["997"],"URL":"https:\/\/doi.org\/10.1186\/s12933-020-00997-7","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,18]]},"assertion":[{"value":"31 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All animal procedures complied with the Guide of Care and the Use of Laboratory Animals published by the U.S. National Institutes of Health (Bethesda, MD, USA; NIH publication number 85\u201323, revised 1996) and authorization was given by the French Ministry of Research (#10073-2017053013335510) after approval by the local Ethics Committee (Comit\u00e9 R\u00e9gional d\u2019Ethique en Mati\u00e8re d\u2019Exp\u00e9rimentation Animale de Strasbourg, CE35).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"This work was supported by an unrestricted research grant from Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19"}}